Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.49 |
| ▸ | PGR | P06401 | 3/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068498 | 0.84 | KEAP1 (0.65) | KEAP1L3MBTL1NFE2L2NR3C1PGR | |
| SCHEMBL29904739 | 0.84 | KEAP1 (0.65) | KEAP1L3MBTL1NFE2L2NR3C1PGR | |
| SCHEMBL26386536 | 0.80 | KEAP1 (0.50) | KEAP1L3MBTL1NFE2L2NR3C1PGR | |
| SCHEMBL22548129 | 0.80 | SIGMAR1 (0.35) | KEAP1L3MBTL1ALDH1A1 | |
| SCHEMBL30659708 | 0.78 | KEAP1 (0.55) | KEAP1L3MBTL1NFE2L2NR3C1PGR | |
| SCHEMBL27183369 | 0.77 | PGAM1 (0.41) | L3MBTL1ALDH1A1 | |
| SCHEMBL3915870 | 0.76 | L3MBTL1 (0.62) | KEAP1L3MBTL1NFE2L2NR3C1PGR | |
| SCHEMBL1476351 | 0.76 | KEAP1 (0.70) | KEAP1L3MBTL1NFE2L2KMT2AEP300 | |
| SCHEMBL1488624 | 0.76 | KEAP1 (0.57) | KEAP1L3MBTL1NFE2L2NR3C1PGR | |
| Methanesulfonamide SCHEMBL9075925 | 0.75 | HTR6 (0.43) | KEAP1L3MBTL1KMT2AEP300KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3696174-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3012250-B1 | ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3208272-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9434688-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| US-9434688-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| US-9434688-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| EP-2078712-B1 | Indole derivatives as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-10 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137202-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-06-23 | — | — | US | disclosed |
| US-6875770-B2 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-04-05 | — | — | US | disclosed |
| US-6872834-B2 | Phenyl-substituted indoles and indazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-08 | — | — | US | disclosed |
| US-6673797-B1 | CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1268421-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001074773-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1086950-A1 | HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | KEAP1 2016/4885L3MBTL1 416/4885NFE2L2 3169/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | KEAP1 2016/4885L3MBTL1 416/4885NFE2L2 3169/4885 |
| US-20050137202-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | PTGS2, IDO2, IDO1 | KEAP1 1306/4885L3MBTL1 4654/4885NFE2L2 52/4885 |
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | IDO1, IDO2, AADAC | KEAP1 1604/4885L3MBTL1 3482/4885NFE2L2 1246/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | KEAP1 2016/4885L3MBTL1 416/4885NFE2L2 3169/4885 |
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | IDO1, PTGS1, IDO2 | KEAP1 1192/4885L3MBTL1 4686/4885NFE2L2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.